Resource Logo
CDC HIV/AIDS/Viral Hepatitis/STD/TB Prevention News Update

EUROPE: EU Expands Use of Roche's Pegasys in Chronic Hepatitis C


Reuters (03.18.13)

On March 18, the pharmaceutical company Roche announced that the European Medicines Agency had expanded approval of its drug Pegasys plus ribavirin for treatment of chronic hepatitis C virus (HCV) infection to include children five years of age and older who have not received treatment and who have tested positive for HCV. According to the drug company, mother-to-child HCV transmission is the most common mode of infection for children, with approximately 65,000 youth now estimated to be living with chronic HCV in Europe. Roche says Pegasys in combination with ribavirin is currently the foundation treatment for chronic HCV in adults.


Copyright © 2013 -CDC Prevention News Update, Publisher. All rights reserved to Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.

Information in this article was accurate in March 19, 2013. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.